BACK of the BOOK
Heard in the Blogosphere
YEAR IN REVIEW
2018 was the biggest year yet for ASH Clinical News. In our fourth year of publication,
our magazine has:
Most Popular Tweets
Here are the most popular Tweets from
@ASHClinicalNews in 2018.
• covered the latest news from national and international hematologic conferences
• reported on everything from Correcting the Gender Imbalance in Medicine to
Resolving Conflicts of Interest in our in-depth Feature articles
• launched our Sound Bites series of exclusive audio from our conversations with
innovators and mentors in hematology
• started publishing How I Treat in Brief, condensed versions of Blood’s popular
“How I Treat” section
Here, we take a look back at 2018.
The Year in Clicks
1. January 29
Obinutuzumab receives @US_FDA approval as frontline
treatment of follicular #lymphoma, based on results from the
GALLIUM study
2. May 13
Wishing a #HappyMothersDay to all
the hematologists and mothers of
hematologists out there! We hope
you got a great gift (maybe some-
thing from ASH-mazon...?)
Here are the year’s most-accessed articles and videos
from ASHClinicalNews.org:
Top 10 Articles
3. October 27
A Date With the #EHR: Doctors spend
approximately 6 hours each work day
interacting with an #EHR system - often
during their off hours
1. FDA Places Point-of-Care CAR T-Cell Trial on Hold (June 21, 2018)
2. How I Treat In Brief: Managing Monoclonal Gammopathy of Undetermined
Significance (July 2018)
3. Ibrutinib Price Triples After Research Hints at Effectiveness of Lower Doses (May
3, 2018)
4. Advice for the Graduating Hematologist by Richard T. Silver, MD (August 2018)
5. Burnout? What Burnout? by Keith Stewart, MBChB, MBA (July 2018)
4. April 1
A CAR T Par-T: Now that the first
#CARTcell therapies have been ap-
proved for leukemia and lymphoma,
what’s next for these revolutionary
treatments?
6. Draining the Email Swamp by David Steensma, MD (November 2018)
7. Not What I Signed up For by Alice Ma, MD (March 2018)
8. Solving the Contract Research Agonization Problem by Mikkael Sekeres, MD, MS
(December 2017)
9. FDA Approves Avatrombopag for Thrombocytopenia (July 20, 2018)
10. What’s in a (Drug) Name? by David Steensma, MD (May 2018)
Top 5 Feature Articles
1. Contract Research Organizations: Outsourced Trials, Outsized Problems (March 2018)
2. Blood Donation: Separating Myth From Fact (January 2018)
3. Are EHRs and Physicians Out of Sync? (April 2018)
4. MOC Machinations (July Bonus Mid-Year Edition 2018)
5. The Pharmacoeconomics of Oral and Self-Administered Cancer Treatments (June 2018)
Top 5 Videos
1.
Highlights of the 2017 ASH Annual Meeting (Mikkael A. Sekeres, MD, MS)
2. Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing (James Berenson, MD)
3. Allogeneic Transplant Plus NK Cells in High-Risk Myeloma (Nina Shah, MD)
4. Expanding Acalabrutinib to Waldenström Macroglobulinemia (Roger Owen, MRCP,
MRCPath, MD)
5. Does Blinatumomab Affect CAR T-Cell Therapy Response? (Bijal Shah, MD)
170
ASH Clinical News
5. July 2
Treatment with gene therapy reduced or eliminated the need
for long-term red blood–cell transfusions in some patients with
severe beta-thalassemia
6. March 9
Written in @BloodJournal: Treatment with blinatumomab
eradicates minimal residual disease #MRD in patients with
acute lymphocytic #leukemia
7. March 19
Written in @BloodJournal: Phase I study finds that adding
ibrutinib to R-ICE induces an overall response rate of 90% in
rel/ref DLBCL #lymphoma
8. July 27
Sticker Shock:
#CARTcell therapy
sounds like a con-
cept plucked from
science fiction, but
the costs of this
revolutionary treat-
ment are straight from a horror film
9. July 29
Early results from a phase I trial find that most #myeloma
patients responded to the triplet combination of ibrutinib plus
carfilzomib and dexamethasone
10. January 30
Big Questions, Tough Answers:
@NCIDirector Ned Sharpless on transi-
tioning from academia to government,
the challenges facing investigators, and
the exciting developments in precision
oncology and translational research
December 2018